| Attribute |
Value |
| 52 Week Change |
0.30441475 |
| Address1 |
79 New Oxford Street |
| All Time High |
76.1875 |
| All Time Low |
0.515625 |
| Ask |
50.7 |
| Ask Size |
500 |
| Average Analyst Rating |
2.9 - Hold |
| Average Daily Volume10 Day |
2,874,970 |
| Average Daily Volume3 Month |
3,913,101 |
| Average Volume |
3,913,101 |
| Average Volume10Days |
2,874,970 |
| Beta |
0.295 |
| Bid |
50.72 |
| Bid Size |
300 |
| Book Value |
11.975533 |
| City |
London |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United Kingdom |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
50.82 |
| Current Ratio |
0.815 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,786,665,600 |
| Day High |
50.88 |
| Day Low |
49.96 |
| Debt To Equity |
106.497 |
| Dividend Date |
1,791,417,600 |
| Dividend Rate |
1.82 |
| Dividend Yield |
3.61 |
| Earnings Call Timestamp End |
1,785,243,600 |
| Earnings Call Timestamp Start |
1,785,243,600 |
| Earnings Growth |
-0.695 |
| Earnings Quarterly Growth |
-0.699 |
| Earnings Timestamp |
1,785,241,800 |
| Earnings Timestamp End |
1,793,190,600 |
| Earnings Timestamp Start |
1,793,190,600 |
| Ebitda |
10,817,999,872 |
| Ebitda Margins |
0.32581002 |
| Enterprise To Ebitda |
10.772 |
| Enterprise To Revenue |
3.51 |
| Enterprise Value |
116,536,868,864 |
| Eps Current Year |
4.79384 |
| Eps Forward |
4.98624 |
| Eps Trailing Twelve Months |
3.25 |
| Esg Populated |
0 |
| Ex Dividend Date |
1,786,665,600 |
| Exchange |
NYQ |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
51.744 |
| Fifty Day Average Change |
-0.9239998 |
| Fifty Day Average Change Percent |
-0.017857138 |
| Fifty Two Week Change Percent |
30.441475 |
| Fifty Two Week High |
61.7 |
| Fifty Two Week High Change |
-10.880001 |
| Fifty Two Week High Change Percent |
-0.17633712 |
| Fifty Two Week Low |
38.63 |
| Fifty Two Week Low Change |
12.189999 |
| Fifty Two Week Low Change Percent |
0.3155578 |
| Fifty Two Week Range |
38.63 - 61.7 |
| Financial Currency |
GBP |
| First Trade Date Milliseconds |
323,101,800,000 |
| Five Year Avg Dividend Yield |
4.32 |
| Float Shares |
1,940,670,240 |
| Forward Eps |
4.98624 |
| Forward P E |
10.192049 |
| Free Cashflow |
3,482,625,024 |
| Full Exchange Name |
NYSE |
| Full Time Employees |
66,841 |
| Fullday Change |
0.549999 |
| Fullday Change Percent |
1.09409 |
| Fullday Price |
50.57 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.73493 |
| Gross Profits |
24,401,999,872 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.00059999997 |
| Held Percent Institutions |
0.17488001 |
| Implied Shares Outstanding |
2,002,805,623 |
| Industry |
Drug Manufacturers - General |
| Industry Disp |
Drug Manufacturers - General |
| Industry Key |
drug-manufacturers-general |
| Ir Website |
http://www.gsk.com/investors.html |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Dividend Date |
1,786,665,600 |
| Last Dividend Value |
0.452 |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,658,448,000 |
| Last Split Factor |
1,226:1000 |
| Long Business Summary |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom. |
| Long Name |
GSK plc |
| Market |
us_market |
| Market Cap |
101,782,585,344 |
| Market State |
CLOSED |
| Max Age |
86,400 |
| Message Board Id |
finmb_275442 |
| Most Recent Quarter |
1,782,777,600 |
| Name Change Date |
2,026-08-29 |
| Net Income To Common |
4,821,000,192 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
100,859,696,152 |
| Number Of Analyst Opinions |
8 |
| Open |
50.22 |
| Operating Cashflow |
8,330,999,808 |
| Operating Margins |
0.30943 |
| Payout Ratio |
0.5679 |
| Peg Ratio |
100.21 |
| Phone |
44 20 8047 5000 |
| Post Market Change |
-0.25 |
| Post Market Change Percent |
-0.4919323 |
| Post Market Price |
50.57 |
| Post Market Time |
1,787,960,678 |
| Prev Name |
GlaxoSmithKline plc |
| Previous Close |
50.27 |
| Price Eps Current Year |
10.601105 |
| Price Hint |
2 |
| Price To Book |
4.243653 |
| Price To Sales Trailing12 Months |
3.0654635 |
| Profit Margins |
0.1452 |
| Quick Ratio |
0.519 |
| Quote Source Name |
Delayed Quote |
| Quote Type |
EQUITY |
| Recommendation Key |
hold |
| Recommendation Mean |
2.875 |
| Region |
US |
| Regular Market Change |
0.549999 |
| Regular Market Change Percent |
1.09409 |
| Regular Market Day High |
50.88 |
| Regular Market Day Low |
49.96 |
| Regular Market Day Range |
49.96 - 50.88 |
| Regular Market Open |
50.22 |
| Regular Market Previous Close |
50.27 |
| Regular Market Price |
50.82 |
| Regular Market Time |
1,787,947,202 |
| Regular Market Volume |
3,432,072 |
| Return On Assets |
0.10007 |
| Return On Equity |
0.33383 |
| Revenue Growth |
0.053 |
| Revenue Per Share |
16.51 |
| Sand P52 Week Change |
0.20204377 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
2,002,805,623 |
| Shares Percent Shares Out |
0.0074 |
| Shares Short |
14,778,190 |
| Shares Short Previous Month Date |
1,784,073,600 |
| Shares Short Prior Month |
13,759,806 |
| Short Name |
GSK plc |
| Short Percent Of Float |
0.0074 |
| Short Ratio |
3.3 |
| Source Interval |
15 |
| Symbol |
GSK |
| Target High Price |
70.0 |
| Target Low Price |
50.0 |
| Target Mean Price |
58.5775 |
| Target Median Price |
56.0 |
| Total Cash |
3,105,999,872 |
| Total Cash Per Share |
1.55 |
| Total Debt |
18,293,000,192 |
| Total Revenue |
33,202,999,296 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.68 |
| Trailing Annual Dividend Yield |
0.013526955 |
| Trailing Eps |
3.25 |
| Trailing P E |
15.636923 |
| Trailing Peg Ratio |
100.2138 |
| Triggerable |
1 |
| Two Hundred Day Average |
52.22045 |
| Two Hundred Day Average Change |
-1.4004517 |
| Two Hundred Day Average Change Percent |
-0.026818069 |
| Type Disp |
Equity |
| Volume |
3,432,072 |
| Website |
https://www.gsk.com |
| Zip |
WC1A 1DG |